Terms ending in 2034
Every in-force patent on Acceleron Pharma Inc.'s record whose computed term ends in 2034, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,809,637 | Transforming Growth Factor Beta Receptor II Fusion Polypeptides In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 10,316,076 | Transforming Growth Factor-Beta Receptor Type II Fusion Polypeptides In force · Medium confidence | Acceleron Pharma Inc. | In force | Medium confidence | |
| US 10,981,973 | Methods of Treating a Sclerotic Disorder by Administering a Transforming Growth Factor Beta Receptor Type II Fusion Polypeptide In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 11,008,377 | Methods of Treating a Fibrotic Disorder by Administering Transforming Growth Factor Beta Receptor II Fusion Polypeptides In force · Medium confidence | Acceleron Pharma Inc. | In force | Medium confidence | |
| US 11,590,201 | Endoglin Peptides to Treat Fibrotic Diseases In force · High confidence | Acceleron Pharma, Inc. | In force | High confidence | |
| US 10,682,392 | Methods for Treating Pulmonary Hypertension with a Tgf-Beta Type II Receptor-Fc Fusion Protein In force · High confidence | The Brigham and Women's Hospital, Inc. | In force | High confidence | |
| US 11,951,156 | Methods for Treating Pulmonary Hypertension with a Ligand Binding Domain of a Tgf-Beta Type II Receptor In force · High confidence | The Brigham and Women's Hospital, Inc. | In force | High confidence | |
| US 12,678,483 | Methods for Treating Pulmonary Disease with a Ligand Binding Domain of a Tgf-Beta Type II Receptor In force · High confidence | The Brigham and Women's Hospital, Inc. | In force | High confidence |
8 of 8 patents shown. Soonest term end first, then patent number.
5 of these are in force and held by Acceleron Pharma Inc..
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.